07:06 EDT Krystal Biotech (KRYS) sees FY26 R&D and SG&A expense $175M-$195M
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech reports Q1 EPS $1.83, consensus $1.42
- KRYS Earnings this Week: How Will it Perform?
- Krystal Biotech: Valuation Reflects Pipeline Optimism Amid Dosing and Efficacy Risks, Justifying a Hold Rating
- Krystal Biotech initiated with a Peer Perform at Wolfe Research
- Krystal Biotech price target raised to $325 from $318 at BofA